Introduction: Cardiovascular disease (CVD) is very common in chronic kidney disease (CKD). Lipoprotein metabolism is impaired in CKD patients, which is a significant risk factor for atherosclerosis and thus CVD. Objective: To investigate the serum lipid profile of patients with chronic kidney disease at CHUD-B/A in 2021. Method: A cross-sectional, descriptive and analytical study was conducted from January 2 to June 30, 2021, at the CHUD-B/A, in adult patients with CKD received in consultation or hospitalized. After ethical consultation, a venous blood sample was taken, followed by the determination of lipid parameters (total cholesterol, HDL cholesterol, triglycerides) by enzymatic colorimetric methods. LDL-cholesterol was calculated according to the formula of Friedwald et al. The plasma atherogenic index (PAI) was obtained by the formula log (triglycerides/HDL-cholesterol). Dyslipidemias was defined according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP/ATP III) classification. Logistic regression was used to identify factors associated with dyslipidemia at the 5% level. Results: A total of 54 patients with CKD were enrolled. The hospital prevalence of dyslipidemia was 64.81%. The different types of dyslipidemia found were HDL hypocholesterolemia (40.74%), LDL hypercholesterolemia (33.33%), hypertriglyceridemia (29.63%), total hypercholesterolemia (24.07%), mixed hyperlipidemia (12.96%), atherogenic dyslipidemia (7.41%). High PAI was the most common with 64.81%. Abdominal obesity was associated with mixed hyperlipidemia (p = 0.0043). HDL hypocholesterolemia was associated with end-stage CKD (p = 0.0001). Obesity (BMI) was a risk factor for LDL hypercholesterolemia (p = 0.0082). Conclusion: The hospital prevalence of dyslipidemia is high in patients with CKD. Serum lipid parameters should be included in the follow-up consultations of CKD patients.
References
[1]
Murton, M., Goff-Leggett, D., Bobrowska, A., Garcia Sanchez, J.J., James, G., Wittbrodt, E., et al. (2020) Burden of Chronic Kidney Disease by KDIGO Categories of Glomerular Filtration Rate and Albuminuria: A Systematic Review. Advances in Therapy, 38, 180-200. https://doi.org/10.1007/s12325-020-01568-8
[2]
Stevens, P.E., O’Donoghue, D.J., de Lusignan, S., Van Vlymen, J., Klebe, B., Middleton, R., et al. (2007) Chronic Kidney Disease Management in the United Kingdom: NEOERICA Project Results. Kidney International, 72, 92-99. https://doi.org/10.1038/sj.ki.5002273
[3]
Webster, A.C., Nagler, E.V., Morton, R.L. and Masson, P. (2017) Chronic Kidney Disease. The Lancet, 389, 1238-1252. https://doi.org/10.1016/s0140-6736(16)32064-5
[4]
Obialo, C.I., Ofili, E.O. and Norris, K.C. (2018) Statins and Cardiovascular Disease Outcomes in Chronic Kidney Disease: Reaffirmation vs. Repudiation. International Journal of Environmental Research and Public Health, 15, Article 2733. https://doi.org/10.3390/ijerph15122733
[5]
Jungers, P., Massy, Z., Khoa, T., Fumeron, C., Labrunie, M., Lacour, B., et al. (1997) Incidence and Risk Factors of Atherosclerotic Cardiovascular Accidents in Predialysis Chronic Renal Failure Patients: A Prospective Study. Nephrology Dialysis Transplantation, 12, 2597-2602. https://doi.org/10.1093/ndt/12.12.2597
[6]
James, M.T., Hemmelgarn, B.R. and Tonelli, M. (2010) Early Recognition and Prevention of Chronic Kidney Disease. The Lancet, 375, 1296-1309. https://doi.org/10.1016/s0140-6736(09)62004-3
[7]
Mikolasevic, I., Žutelija, M., Mavrinac, V. and Orlic, L. (2017) Dyslipidemia in Patients with Chronic Kidney Disease: Etiology and Management. International Journal of Nephrology and Renovascular Disease, 10, 35-45. https://doi.org/10.2147/ijnrd.s101808
[8]
Adejumo, O.A., Okaka, E.I. and Ojogwu, L.I. (2016) Lipid Profile in Pre-Dialysis Chronic Kidney Disease Patients in Southern Nigeria. Ghana Medical Journal, 50, 44-49. https://doi.org/10.4314/gmj.v50i1.7
[9]
Ganta, V., Yalamanchi, R., KC, M., Sahu, B., Raghvendar, K., Anusha, G., et al. (2016) A Study of Lipid Profile in Non-Diabetic Chronic Kidney Disease. International Journal of Advances in Medicine, 3, 965-970. https://doi.org/10.18203/2349-3933.ijam20163732
[10]
Chijioke, A., Makusidi, A.M., Shittu, O.A., Sanni, M.A., Biliaminu, S.A., Abdul-Rahman, S., et al. (2011) Pattern of Lipid Profile in Dialysis Naïve Patients from Ilorin, Nigeria. The Internet Journal of Nephrology, 6, 1-7.
[11]
Mshelia, D.S., Brutai, L.B. and Mamza, Y.P. (2002) Lipid Profile in Predialysis Patients Chronic Kidney Disease Patients Attending University of Maiduguri Teaching Hospital, Nigeria. Nigerian Journal of Clinical Practice, 12, 173-178.
[12]
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). The Journal of the American Medical Association, 285, 2486-2497. https://doi.org/10.1001/jama.285.19.2486
[13]
Assoumanou, M., Agniwo, C., Soumanou, M. and Akpona, S. (2011) Intérêt de la technique de précipitation au sulfate de dextrane dans la détermination du cholestérol-LDL. International Journal of Biological and Chemical Sciences, 4, 2237-2244. https://doi.org/10.4314/ijbcs.v4i6.64942
[14]
Dobiás̆ová, M. and Frohlich, J. (2001) The Plasma Parameter Log (TG/HDL-C) as an Atherogenic Index: Correlation with Lipoprotein Particle Size and Esterification Rate Inapob-Lipoprotein-Depleted Plasma (FERHDL). Clinical Biochemistry, 34, 583-588. https://doi.org/10.1016/s0009-9120(01)00263-6
[15]
Improving Global Outcomes (Kdigo) CKD Work Group (2012) Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International, 3, 1-150.
[16]
Elmachtani Idrissi, S., Dami, A., Bouhsain, S., Ouzzif, Z., Aatif, T., El mezouari, M., et al. (2011) Lipid Profile of Patients on Chronic Hemodialysis (Morocco). Cahiers Santé, 21, 27-31. https://doi.org/10.1684/san.2011.0233
[17]
Ladhari, N., Ben Nacef, I., Chargui, S., Jerbi, M., Gaied, H., El Younsi, F., et al. (2016) Prévalence de la dyslipidémie chez les hémodialysés. Annales d’Endocrinologie, 77, 542. https://doi.org/10.1016/j.ando.2016.07.895
[18]
Deepak, J., Aggarwal, K., Singh, S., Bishnoi, A. and Deepak, Y. (2019) Evaluation of Lipid Profile in Patients of Chronic Kidney Disease. International Journal of Science and Research, 8, 75-78.
[19]
Ganesan, K. and Ramesh, N. (2019) A Study of Lipid Profile and ECG Changes in Chronic Kidney Disease Patients. Institute of Advanced Investment Management.
[20]
Aljabri, K. (2019) Serum Lipid Profiles in Patients with Chronic Kidney Disease in a Saudi Population. Endocrinology&Metabolism International Journal, 7, 41-46. https://doi.org/10.15406/emij.2019.07.00239
[21]
Mondal, E., Khan, M.M., Hossain, M.I., Moshwan, M.M., Saha, R., et al. (2021) The Pattern of Lipid Profile in Patients with Chronic Kidney Disease. Mymensingh Medical Journal, 30, 48-55.
[22]
Llisterri Caro, J.L., Gorriz Teruel, J.L., Alonso Moreno, F.J., Manzanera Escribano, M.J., Rodríguez Roca, G.C., Barrios Alonso, V., et al. (2008) Prevalencia de la enfermedad renal crónica oculta en la población dislipémica asistida en atención primaria. Estudio LIPICAP. Medicina Clínica, 130, 127-132. https://doi.org/10.1157/13115785
[23]
Kaba, M., Diakite, M., Bah, A., Sylla, I., Cherif, I., Tolno, A., et al. (2010) Profil Lipidique des Urémiques a L’hôpital National de Donka a Conakry. Dyslipidemia in Ureamic Patients at the National Hospital of Donka-Conakry. Médecine d’Afrique Noire, 57, 255-258.
[24]
Carmena, R., Duriez, P. and Fruchart, J. (2004) Atherogenic Lipoprotein Particles in Atherosclerosis. Circulation, 109, 102-107. https://doi.org/10.1161/01.cir.0000131511.50734.44
[25]
Charlton-Menys, V., Betteridge, D.J., Colhoun, H., Fuller, J., France, M., Hitman, G.A., et al. (2009) Targets of Statin Therapy: LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B in Type 2 Diabetes in the Collaborative Atorvastatin Diabetes Study (Cards). Clinical Chemistry, 55, 473-480. https://doi.org/10.1373/clinchem.2008.111401
[26]
Brewer, H.B. (2011) The Evolving Role of HDL in the Treatment of High-Risk Patients with Cardiovascular Disease. The Journal of Clinical Endocrinology & Metabolism, 96, 1246-1257. https://doi.org/10.1210/jc.2010-0163
[27]
Chapman, M.J., Ginsberg, H.N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A.L., et al. (2011) Triglyceride-rich Lipoproteins and High-Density Lipoprotein Cholesterol in Patients at High Risk of Cardiovascular Disease: Evidence and Guidance for Management. European Heart Journal, 32, 1345-1361. https://doi.org/10.1093/eurheartj/ehr112
[28]
Pischon, T., Girman, C.J., Sacks, F.M., Rifai, N., Stampfer, M.J. and Rimm, E.B. (2005) Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B in the Prediction of Coronary Heart Disease in Men. Circulation, 112, 3375-3383. https://doi.org/10.1161/circulationaha.104.532499
[29]
Liang, X., Ye, M., Tao, M., Zheng, D., Cai, R., Zhu, Y., et al. (2020) The Association between Dyslipidemia and the Incidence of Chronic Kidney Disease in the General Zhejiang Population: A Retrospective Study. BMC Nephrology, 21, Article No. 252. https://doi.org/10.1186/s12882-020-01907-5
[30]
Ritchy, R., Benja, L., Harinjara, R. and Narindra, L. (2019) Dyslipidémie Chez Les Malades Rénaux Chroniques. Journal of Current Medical Research and Opinion, 2, 248-251. https://doi.org/10.15520/Jcmro.V2i09.205
